SEC Form 4 · accession 0001203311-16-000173
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan G Drachman
Officer — CMO & EVP, R & D
Period of report
Nov 9, 2016
Accepted (ET)
Nov 14, 2016 · 5:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 9, 2016 | M | 7,751 | $11.09 | A | 117,588 | D | |
| Common StockF1 | Nov 9, 2016 | S | 7,751 | $66.75 | D | 109,837 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $11.09 | Nov 9, 2016 | M | 7,751 | D | — | Aug 27, 2018 | Common Stock | 7,751 | 40,000 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Shares vested at a rate of 25% on 8/27/09 and monthly thereafter until all the shares were fully vested on 8/27/12.